These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32275841)

  • 1. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
    Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
    Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
    Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
    Elife; 2015 Aug; 4():. PubMed ID: 26271008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
    Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
    Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
    Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
    Nat Commun; 2013; 4():2996. PubMed ID: 24356649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
    Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-associated mutant p53 drives the Warburg effect.
    Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
    Nat Commun; 2013; 4():2935. PubMed ID: 24343302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.
    Olotu FA; Soliman MES
    J Cell Biochem; 2018 Mar; 119(3):2646-2652. PubMed ID: 29058783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
    Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
    Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP.
    Valentino E; Bellazzo A; Di Minin G; Sicari D; Apollonio M; Scognamiglio G; Di Bonito M; Botti G; Del Sal G; Collavin L
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7623-7628. PubMed ID: 28667123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
    Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
    Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
    Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
    Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
    J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.